NASDAQ · PASW

Ping An Biomedical Co.., Ltd.

$0.12 -$0.01 (-4.52%) 1D After hours

Key Metrics

$15.44M
Market cap
P/E · TTM
Revenue · TTM
Net income
EPS · TTM
Dividend yield 62.2%
Free cash flow
Beta · 1Y 1.25
EBITDA · TTM
Gross margin

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 27
    From its Feb 9 high, the share price fell 56%.

    Peak close $0.27 on Feb 9; trough close $0.12 on Jul 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -56%
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Feb 17
    The stock moved -19.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 17
  • Feb 9
    The stock moved +21.8% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Feb 9

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$15.44M
Enterprise value
Shares outstanding124.6M
52-wk range$0.11 – $1.22
Avg volume · 20D1.4M
Net cash
Book value / share$0.05
ExchangeNASDAQ
About Ping An Biomedical Co.., Ltd.
IPO dateJul 18, 2025
Employees7

Ping An Biomedical Co Ltd formerly Majestic Ideal Holdings Ltd is a Cayman Islands-based holding company, conducting operations through its PRC subsidiary, NewBrand.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S
P/FCF
EV/EBITDA
EV/Sales
Graham №

Profitability

Gross
Operating
Net
FCF
ROE / ROIC — · —

Financial Health

Current ratio2.76
Quick ratio2.74
Debt / equity
Debt / EBITDA
Net cash
Working capital$5.71M

Cash Flow · TTM

Operating CF −$902.90K
Capex
Free cash flow
Buybacks
Dividends paid $9.60M
Shareholder yield 62.2%

Piotroski F-Score

Needs two fiscal years of filings

Altman Z-Score

Insufficient balance-sheet inputs

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-09-30 · computed by TickerWolf from SEC filings